Mapping the intellectual structure of the research of omalizumab in chronic spontaneous urticaria: A bibliometric analysis

Abstract

BackgroundGuidelines for treating Chronic Spontaneous Urticaria (CSU) recommend using the IgE-targeted biologic Omalizumab in patients with antihistamine-refractory disease. ObjectiveTo present a bibliometric review of publications related to Omalizumab and CSU over the past two decades. MethodsPublications that are relevant from 2003 to 2022 were extracted from the Science Citation Index-Expanded (SCI-EXPANDED) in the Web of Science Core Collection (WoSCC) database as of January 8, 2023. We utilized CiteSpace (version 6.1.R3), VOSviewer (version 1.6.18), and the R package (version 4.2.1) to analyze and visualize the data. The R package bibliometrix (version 4.2.1) was also used. ResultsBetween 2003 and 2022, a total of 566 articles were published. Since 2014, there has been a rapid increase in publication outputs. According to the collaboration network, the most influential country/institute/scholar was the USA, Charité Universitätsmedizin Berlin, and Maurer Marcus, respectively. The study identified the Journal of Allergy and Clinical Immunology: In Practice as the most productive journal and the Journal of Allergy and Clinical Immunology as the most co-cited journal. The analysis of keywords revealed that high-frequency terms such as angioedema, IgE, treatment, anti-IgE, asthma, and atopic dermatitis were present. Moreover, recent studies in this area have mainly concentrated on biomarkers, Dupilumab, and COVID-19. ConclusionThere has been a growing interest in the use of Omalizumab in CSU in recent years. The current trending topics in this research are the identification of biomarkers and the development of new monoclonal antibodies for the treatment of CSU.